CD8 (cluster of differentiation 8)

GLUT1 shows compartment- and context-dependent associations in the CRLM. While tumor-core GLUT1 is linked to proliferative activity, invasive-margin GLUT1 is associated with favorable outcomes in solitary metastases. Immunofluorescence and functional data provide hypothesis-generating context and warrant validation with quantitative spatial immune profiling and independent cohorts.

However, this restorative effect of arginine is significantly dependent on its action on macrophages. Our findings establish low-protein diet-induced hypoalbuminemia as a key driver of immunotherapy resistance, unveil a novel metabolic-immune circuit centered on TAM arginine metabolism, and identify arginine replenishment as a potential therapeutic strategy to reverse immune suppression in hypoalbuminemia patients.

They suppress SCLC antigen presentation via ferroptosis-dependent/independent mechanisms, limiting T cell function. TRIM36 and CAMK2N2 are promising SCLC biomarkers and therapeutic targets, providing clues to unravel ferroptosis-antigen presentation associations in tumor cells and optimize immunotherapeutic strategies.

Future directions include multicenter prospective trials to validate multimodal models, standardize detection methods, and increase interdisciplinary collaboration. By integrating genomic, epigenetic, metabolic, and microbiome data, these models can better capture the complexity of PDAC, thereby improving patient outcomes through precision immunotherapy.

ATAD2 drives immunotherapy resistance in LUAD by activating an ATAD2-LDHA-LA axis that impairs CD8+ T cell function. Targeting ATAD2 may broadly restore antitumor immunity and enhance the efficacy of T cell-based immunotherapies.

Moreover, the synergistic mechanisms with immunotherapy remain largely hypothetical, supported by limited in vivo studies. By addressing these barriers through interdisciplinary collaboration, FLASH-RT may eventually advance precision radio-immunotherapy, but substantial translational research is still required before it can supplant conventional paradigms.

In contrast, a patient with loss of BAP1 was linked to a CD8+ T-cell enriched tumor microenvironment, classified as spatially immune enriched and responded long-term to subsequent immune checkpoint inhibition and tyrosine kinase inhibition therapy. These observations provide a rationale for integrated genomic and spatial immune profiling in BTC, which will require further prospective validation.

NCT05286814 is a phase II non-randomized trial evaluating subcutaneous PDS01ADC in combination with HAIP floxuridine and systemic chemotherapy (FOLFOX or FOLFIRI) in patients with unresectable microsatellite stable or mismatch repair-proficient colorectal liver metastases previously treated with at least one line of systemic chemotherapy...Addition of PDS01ADC is not detrimental to HAIP therapy and is associated with both systemic and intratumoral immune modulation. Initial results warrant continuation to full enrollment for further evaluation of clinical and scientific endpoints.

This study deciphered a novel druggable metabolic-epigenetic pathway (lactate-H3K18la-KIF20A-Myc-PD-L1) responsible for immune evasion in HCC. Targeting this axis might offer a promising strategy to reprogram the tumor microenvironment and restore immunotherapy sensitivity.

Induction of ONECUT1 suppresses hepatoblastoma progression by inhibiting tumor cell growth and by reshaping the tumor immune microenvironment. These findings reveal a previously unrecognized antitumor role of ONECUT1 during hepatoblastoma progression and suggest that restoring ONECUT1 activity may represent a promising therapeutic strategy for this pediatric malignancy.

These findings reveal the dual oncogenic function of NSUN2 in COAD-it not only propels tumor progression through direct signaling activation but also enables immune evasion by attenuating anti-tumor immunity. In summary, this study systematically clarifies how NSUN2 promotes COAD development by simultaneously activating the Wnt/β-catenin pathway and suppressing CD8+ T-cell-mediated immunity, providing a strong mechanistic foundation for its potential as a therapeutic target in future COAD treatment strategies.

Consistently, single-cell analysis of colorectal tumors shows PUM1 positively correlates with PD-L1 and inversely with CD8+ T cell infiltration. Together, our study defines a novel IFN-γ-responsive post-transcriptional regulation that controls PD-L1 expression and tumor immune suppression.